Lifecore Biomedical to Participate in Upcoming Investor and Industry Conferences

Lifecore Biomedical to Participate in Upcoming Investor and Industry Conferences

February 26, 2025 | Last Trade: US$6.41 0.07 1.10

CHASKA, Minn., Feb. 26, 2025 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore”), a fully integrated contract development and manufacturing organization (“CDMO”), today announced that the company will participate in multiple upcoming investor conferences and industry events. Details regarding Lifecore’s participation are as follows:

TD Cowen 45^th Annual Health Care Conference
Details: Paul Josephs, chief executive officer, will deliver a corporate presentation and Lifecore management will participate in investor meetings
Presentation Date/Time: Tuesday, March 4, 2025, 9:50 – 10:20 a.m. ET
Conference Dates: March 3-5, 2025
Location: Boston, MA

KeyBanc Capital Markets Healthcare Forum
Details: Mr. Josephs will participate in a fireside chat and Lifecore management will participate in investor meetings
Fireside Chat Date/Time: Wednesday, March 19, 2025, 3:00 – 3:35 p.m. ET
Conference Dates: March 18-19, 2025
Location: Virtual

DCAT Week 2025
Details: Lifecore team will participate in meetings with current and prospective customers and attend networking events
Conference Dates: March 17-20, 2025
Location: New York, NY

A live webcast of the TD Cowen presentation may be accessed via a link on Lifecore’s investor website on the Investor Events & Presentations page at: https://ir.lifecore.com/events-presentations. Additionally, a replay of the webcast will be available on the Lifecore website following the conference.

About Lifecore Biomedical

Lifecore Biomedical, Inc. (Nasdaq: LFCR) is a fully integrated contract development and manufacturing organization (CDMO) that offers highly differentiated capabilities in the development, fill and finish of sterile injectable pharmaceutical products in syringes, vials, and cartridges, including complex formulations. As a leading manufacturer of premium, injectable-grade hyaluronic acid, Lifecore brings more than 40 years of expertise as a partner for global and emerging biopharmaceutical and biotechnology companies across multiple therapeutic categories to bring their innovations to market. For more information about the company, visit Lifecore’s website at www.lifecore.com.

Stock Quote

Last Trade:	US$6.41
Daily Change:	0.07 1.10
Daily Volume:	193,677
Market Cap:	US$237.180M

April 03, 2025 Lifecore Biomedical Reports Third Quarter Fiscal 2025 Financial Results and Provides Corporate Update March 17, 2025 Humanetics Selects Lifecore Biomedical to Deliver CDMO Services Supporting Development of BIO 300 for the Prevention of Acute Radiation Syndrome January 07, 2025 Lifecore Biomedical Further Strengthens Financial Position Through Sale of Excess Capital Equipment for $17 Million January 02, 2025 Lifecore Biomedical Reports Second Quarter Fiscal 2025 Financial Results and Provides Corporate Update December 19, 2024 Lifecore Biomedical Selected by Nirsum Labs to Provide CDMO Services Supporting Clinical Development of Innovative Opioid Use Disorder Treatment LOAD MORE NEWS

Featured Stock

Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....

CLICK TO LEARN MORE

Featured Stock

Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...

CLICK TO LEARN MORE